HR 2241
114th Congress
House
International Affairs
Child health
Congressional oversight
Drug therapy
Foreign aid and international relief
HIV/AIDS
Health programs administration and funding
Health promotion and preventive care
Health technology, devices, supplies
Immunology and vaccination
Infectious and parasitic diseases
Medical tests and diagnostic methods
Product development and innovation
Public-private cooperation
U.S. Agency for International Development (USAID)
Women's health
World health
Global Health Innovation Act of 2015
Introduced: May 5, 2015
See on congress.gov
Everywhere this bill has been
13 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 18, 2015
Received in the Senate and Read twice and referred to the Committee on Foreign Relations.
Dec 18, 2015
Motion to reconsider laid on the table Agreed to without objection.
Dec 18, 2015
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR 12/16/2015 H9348)
Dec 18, 2015
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR 12/16/2015 H9348)
Dec 18, 2015
Considered as unfinished business. (consideration: CR H10696)
Dec 16, 2015
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Royce objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
Dec 16, 2015
DEBATE - The House proceeded with forty minutes of debate on H.R. 2241.
Dec 16, 2015
Considered under suspension of the rules. (consideration: CR H9348-9349; text of measure as introduced: CR H9348)
Dec 16, 2015
Mr. Royce moved to suspend the rules and pass the bill, as amended.
Nov 5, 2015
Ordered to be Reported (Amended) by Unanimous Consent.
Nov 5, 2015
Committee Consideration and Mark-up Session Held.
May 5, 2015
Referred to the House Committee on Foreign Affairs.
May 5, 2015
Introduced in House
Plain-English summary
Global Health Innovation Act of 2015
(Sec. 2) This bill directs the U.S. Agency for International Development (USAID) to report annually for four years to Congress regarding:
- the extent to which global health innovations include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations;
- how innovation has advanced USAID's commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases;
- how goals are set for health product development in relation to USAID's health-related goals;
- how USAID is leveraging U.S. investments to achieve greater impact in health innovation, developing and introducing affordable global health products, and increasing health innovations in the development pipeline;
- how USAID is coordinating with other federal departments and agencies in support of global health product development; and
- how USAID is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.
What's happening now
Received in the Senate and Read twice and referred to the Committee on Foreign Relations.
Committees of jurisdiction
2